



Montreal Neurological  
Institute/Hospital



McGill University

# Change Detection and Quantification in Multiple Sclerosis

**D. Louis Collins**  
**Sept 26, 2004**

# Multiple Sclerosis

- **Motivations**
- **Volume change**
  - Global (BICCR)
  - Regional (GM, ventricles, lobes)
  - Local (around lesions)
- **Clinical trial**
  - BICCR results
  - VBM results
- **Deformation modeling**
  - Where and When?

# Motivation

- Clinical surrogates of disease burden in MS are highly variable (EDSS, MSFC)
- MRI shows lesions in vivo




$T_1$ -w




PD



$T_2$ -w



MTR



Gado

# Motivation

- Clinical surrogates of disease burden in MS are highly variable (EDSS, MSFC)
- MRI shows lesions in vivo
- MRI = 10 \* clinical activity

# MRI activity

QuickTime™ and a  
YUV420 codec decompressor  
are needed to see this picture.

## MRI shows brain atrophy in MS



normal



MS

# Motivation

- Clinical surrogates of disease burden in MS are highly variable (EDSS, MSFC)
  - MRI shows lesions in vivo
  - MRI = 10 \* clinical activity
- > MRI-based surrogates of disease burden

# MRI-based surrogates

- **T2 and Gado-based lesion metrics**
    - have shown treatment effects
    - are weakly correlated with disability
  - **CNS atrophy**
    - associated with neuronal/axonal loss
    - associated with irreversible neurological impairment
    - strong correlations with disability
- ⇒ **CNS atrophy may be a better surrogate**




# Methodological Requirements

- **Reproducible**
- **Sensitive to change**
- **Accurate**
- **Practical**

# Data acquisition issues

- **Resolution requirements**
  - Thin slices to reduce partial volume effects
  - Contiguous acquisitions (no slice gap)
  - Prefer 3D acquisitions over 2D
- **Contrast**
  - T1 with or w/o T2/PD
- **Time constraints**
  - Short acquisition to minimize motion artifacts


# BICCR: Brain to IntraCranial Capacity Ratio



# Measuring Changes in Brain Volume Atrophy

- Scan-rescan COV of BPF, BICCR = 0.2%
- Smallest detectable change ~0.5%

# BICCR by Age: Normal Controls





Data from ICBM project, courtesy A Evans

	Pearson	p	coef.	R <sup>2</sup>
all (n=149)	-0.27	.0021	-0.175%/y	7%
women (n=64)	-0.18	.30	-0.215%/y	4%
men (n=85)	-0.34	.0028	-0.167%/y	11%


In agreement with the work of

- Jernigan (1990)  
aging associated with  $\uparrow$  CSF,  $\downarrow$  GM
- Gur (1991), Blatter (1995), Coffey (1998) larger loss in men than in women

# BICCR in MS




# BICCR by EDSS



	Spearman	P	R <sup>2</sup>
ALL (n=28)	-0.496	.0005	24%
RR (n=48)	-0.321	.01	9%
SP (n=22)	-0.682	.0005	46%

# BICCR by Duration of Disease



	Pearson	P	coef.	R <sup>2</sup>
all (n=70)	-0.611	.0000	-0.393%/y	37%
RR (n=48)	-0.488	.0004	-0.273%/y	24%
SP (n=22)	-0.636	.001	-0.418%/y	40%




# **Clinical Trial Analysis**

**Analysis of PRISM baseline-year 2 data**

## BICCR: total loss over 2 (all data)


- No differences between groups when comparing the BICCR value at baseline, year 1 or year 2.
- Repeated measures ANOVA showed no differences between groups for year 2 or for the entire 2 year period.



Post-hoc	1.00000		
Tukey:	0.86135	1.00000	
	0.15724	0.40519	1.00000

## BICCR: loss year 1 All data

- However, there was a slight difference ( $p=0.00448$ ) between rebif44 and placebo in year 1, with rebif44 causing a larger brain volume loss than placebo (or rebif22, but the latter was not significant).



Post-hoc	1.00000		
Tukey:	0.48267	1.00000	
	0.00421	0.11984	1.00000

# Detection of Regional Atrophy

QuickTime™ and a  
Photo decompressor  
are needed to see this picture.

# ANIMAL+INSECT




stereotaxic atlas

ANIMAL





Inverse  
nonlinear



customized atlas




Anatomical  
masking



INSECT







classification



classified tissues



## Regional GM Quantification - Method



# Regional GM Volumes


whole brain:

NC > MS,  $t = 4.4$ ,  $p < .0001$

NC > RR, NC > SP,  $F = 12.3$ ,  $p < .0001$

NC > RR > SP  
 $F = 21.5$ ,  $p < .0001$

NC > RR > SP  
 $F = 16.2$ ,  $p < .0001$



NC > SP  
 $F = 6.8$ ,  $p = .0003$

NC > SP  
 $F = 8.2$ ,  $p < .0001$


NC > SP  
 $F = 9.9$ ,  $p < .0001$

NC > SP  
 $F = 8.5$ ,  $p < .0001$




# Local atrophy estimation


# Longitudinal registration










# 3D Deformation field




# Local atrophy




Successive Non-linear Registration



# Results-Local Atrophy



patient



control




**What about voxel-based image  
analysis of groups?**

**(SPM, VBM)**

# Stereotaxic Space

J. Talairach and P. Tournoux, Co-planar stereotactic atlas of the human brain: 3-Dimensional proportional system: an approach to cerebral imaging, Stuttgart, Georg Thieme Verlag, 1988

- based on anatomical landmarks (anterior and posterior commissures)
- originally used to guide blind stereotaxic neurosurgical procedures (thalamotomy, pallidotomy)
- now used by NeuroScientific community for interpretation and comparison of results






# Difference images

Year 1-0


Year 2-1

Year 2-0


placebo



Treatment 1






Treatment 2



**But what is really significant?**



# Voxel based morphometry




# Difference images

Year 1-0


Year 2-1

Year 2-0


placebo



Treatment 1




Treatment 2




# Voxel-based morphometry



placebo



Treatment 1



Treatment 2

# Deformation Modeling and the ms-mni database (a.k.a. pretty blobs)


Andrew L Janke  
<rotor@cmr.uq.edu.au>

# Why?



- Provides a wealth of preliminary information on where to direct further processing
- “VBM with a time dimension”
- Possible prediction on novel patients

# Previously investigative techniques

- **VBM - Voxel based morphometry**
  - Wright et al., NeuroImage. 1995
  - Ashburner et al, NeuroImage. 1999
- **Deformation based morphometry**
  - Ashburner et al, Human Brain Mapping. 2000
- **Vector deformations analyses**
  - Ashburner J et al, Human Brain Mapping. 1998
  - Gaser C et al, NeuroImage. 1999
  - Thompson et al, Cerebral Cortex. 1998



Janke et al 2000



Thompson et al 2000

# The Processing Pipeline


- **Data**
  - ~4200 data sets, 780 scanning points, 230 patients
- **Pre Processing**
  - Rough inter-scan normalisation via clamping between histogram thresholds
  - Intensity corrected (N3)
- **Registration**
- **Modeling**

# MS patient progression #1





## MS patient progression #2




# **It's average space Jim ...**


**(but not as we knew it)**

- **Linear averaging is not good enough for abnormal structure**
- **Need custom targets on a per-disease or even per-study basis**
- **Also need non-linear average targets to register to.**
  - **Chickens and eggs....**


# Target creation

- First register all linearly to a model (icbm\_152)
- Build a new model (ms01lin)
- Nonlinearly register all to this model again
- Repeat....






Iter: 1                      2                      3                      4                      5                      6



# Mean and SD Evolution



# Once finally in average space..

- **Non-linear deformations are computed between each of the time points**
- **The non-linear grids are then resampled to the average space**
  - Yes, transforming a non-linear transform with a non-linear transform.
  - Or, just compute them in average space (less clean but probably easier to understand)




# Deformations for an Individual




# Deformation Metrics 1

- Volume Loss / Increase
  - Volume dilation - Trace of the deformation field.  
(Worsley & Chung 1999)
  - Intensity encodes the magnitude of the dilation









real: 26.6667	ROI:	real: -1.15686	ROI:	real: -0.491868	ROI:
W: 30.00	-15.00 15.00 0.00	W: 30.00	-15.00 15.00 1.00	W: 30.00	-15.00 15.00 0.00
0.00	39.20	-5.00	5.00	-0.50	0.50
R: grey hot spect blurred grey		R: grey hot spect blurred		R: grey hot spect blurred blurred	
li/mini07/data/rotor/ms-mni/ms01.lin/mp_dunk6162.2000-02-21_mri_t1x.ms01.lin.mnc	/ Browse...	mp_dunk6162.2000-02-21_to_2000-06-15_grid_0.mnc	/ Browse...	blob.mnc	/ Browse...

# Results are 4D..


- RR average results
- Top
  - Std transverse determinant image
- Bottom
  - Y vs Duration slice
  - 'z dimension' is actually duration



# EDSS





# Duration



# Changing change and change progression

## Cheat Sheet



# Conclusions

- **Ability to follow longitudinal change**
  - Methodology is not limited to any particular score
- **Characterisation and localisation**
- **Caveat Emptor**
  - Choice of deformation metric and Interpretation
  - *A physiological process should be easily inferable*